This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.
In this slideshow, we highlight newly released treatment recommendations for rheumatic disease patients undergoing total hip or total knee arthroplasty.
Rheumatic patients are more prone to complications post knee and hip surgery. Two physician associations have penned new treatment guidelines.
Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.
Chronic back pain, arthritis and enthesitis are among common axSpA manifestations, but no two patients are alike. Here, we highlight key presentations.
EULAR-ASAS have updated the 2010 guidelines for axSpA emphasizing treat to target, tapering and for the first time, cost considerations.
In this slideshow, we highlight the 13 ASAS-EULAR treatment management guidelines for axial spondyloarthritis.
Psoriatic spondyloarthritis forms part of the spondyloarthritis spectrum, between peripheral-only psoriatic arthritis and ankylosing spondylitis.
Secukinumab relieves the clinical signs and symptoms of ankylosing spondylitis at two years, shows a study published in the Annals of the Rheumatic Diseases.
TNF-α inhibitor treatment in PsA, RA and AS may be associated with a significant increase in total cholesterol, triglycerides and the atherogenic index. Statins with treatment lowered LDL levels.